Cyclic thrombocytopenia related to erythropoietin-dependent anti-platelet anti-GPIV/IIIb antibody in hemodialysis

J Nephrol. 2022 Jun;35(5):1525-1529. doi: 10.1007/s40620-022-01348-3. Epub 2022 May 21.

Abstract

We describe herein the case of a 65-year-old patient on chronic hemodialysis with a medical history of idiopathic thrombocytopenia who experienced numerous episodes of severe thrombocytopenia with no specific diagnosis. Further analysis of the evolution of the platelet count showed that cyclic thrombocytopenia occurred after each injection of recombinant erythropoietin (rHu-EPO). Exploration of the involved mechanisms revealed the presence of a rHu-EPO-dependent anti-GPIV/IIIb antibody associated with a significant increase in GPIV/IIIb expression on her platelets after the addition of rHu-EPO. EPO was discontinued and the patient was treated with roxadustat with favorable results on her hemoglobin and platelet counts.

Keywords: Hemodialysis; Recombinant erythropoietin; Roxadustat; Thrombocytopenia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Epoetin Alfa
  • Erythropoietin* / therapeutic use
  • Female
  • Humans
  • Recombinant Proteins / adverse effects
  • Renal Dialysis / adverse effects
  • Thrombocytopenia* / chemically induced
  • Thrombocytopenia* / diagnosis
  • Thrombocytopenia* / drug therapy

Substances

  • Recombinant Proteins
  • Erythropoietin
  • Epoetin Alfa

Supplementary concepts

  • Thrombocytopenia, cyclic